Eton licenses U.S. marketing rights to ultra-rare disease product candidate

Eton Pharmaceuticals (ETON) announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved, the product is expected to be the first and only generic alternative to a product used to treat an ultra-rare condition that impacts fewer than 100 patients in the U.S. The licensed product is currently under review with the FDA and is expected to be approved and launched in mid-2026. The company will provide additional product details upon approval.